Recently, the ablation or inhibition of EIF5A2 was also reported to enhance the chemosensitivity of HCC (hepatocellular carcinoma) cells to 5-fluorouracil (5-FU)/doxorubicin and breast cancer cells and bladder cancer cells to doxorubicin [6–9]. The gene discussed is EIF5A2; the disease is breast cancer.